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Chemotherapy for lung cancer not only has severe side effects but frequently also exhibits limited, if any clinical effectiveness.
Dexamethasone (DEX) and similar glucocorticoids (GCs) such as prednisone are often used in the clinical setting, for example, as
cotreatment to prevent nausea and other symptoms. Clinical trials evaluating the impact of GCs on tumour control and patient
survival of lung carcinoma have never been performed. Therefore, we isolated cancer cells from resected lung tumour specimens and
treated them with cisplatin in the presence or absence of DEX. Cell number of viable and dead cells was evaluated by trypan blue
exclusion and viability was measured by the MTT-assay. We found that DEX induced resistance toward cisplatin in all of 10 examined
tumour samples. Similar results were found using gemcitabine as cytotoxic drug. Survival of drug-treated lung carcinoma cells in the
presence of DEX was longlasting as examined 2 and 3 weeks after cisplatin treatment of a lung carcinoma cell line. These data
corroborate recent in vitro and in vivo xenograft findings and rise additional concerns about the widespread combined use of DEX
with antineoplastic drugs in the clinical management of patients with lung cancer.
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The incidence of lung cancer has increased considerably over the
past 50 years and lung carcinoma has become the leading cause of
death by cancer in both men and women (Levi et al, 2004). The
prognosis is still poor and about 80% of patients die within 1 year
of diagnosis (Office for National Statistics, 1997). Despite some
advances in surgical procedures, chemotherapy and radiotherapy
made over the past two decades, long-term survival in, for example,
non-small-cell lung cancer (NSCLC) patients at stage 3 and 4 is
obtained in only 5–10% of cases (Cancer Research UK, 2004). The
development of drug resistance in patients receiving chemotherapy
or a combination therapy including ionizing radiation represents a
major problem in cancer treatment. The present paper aims at
addressing one aspect of this complex problem.
Dexamethasone (DEX) and similar glucocorticoids (GCs) were
first introduced to tumour therapy on the basis of proapoptotic
effects in lymphoid cells and on their effectiveness in treating
tumour-related oedema, inflammation, pain and electrolyte
imbalance as well as stimulating appetite, and most importantly,
preventing nausea and emesis caused by cytotoxic drugs (Aapro,
1991; Cheng et al, 1997; Kirkbride et al, 2000; The Italian Group of
Anticancer Research, 1995, 2000). However, prospective rando-
mised trials evaluating a potential impact on tumour control and
patient survival have never been performed.
Induction of apoptosis resistance toward chemotherapy by DEX
was recently described in a cervical and a lung carcinoma cell line
(Herr et al, 2003) as well as in a breast cancer cell line (Wu et al,
2004). In vivo, a xenografted and cisplatin-treated lung tumour cell
line grew faster in the presence of DEX (Herr et al, 2003). These
results and earlier observations of DEX-induced resistance to a
broad range of cytotoxic anticancer agents (Rutz, 2002; Rutz and
Herr, 2004) suggest that DEX acts proapoptotic in lymphoid but
antiapoptotic in cervical, lung and breast cancer cell lines.
To analyse whether DEX might also induce cisplatin resistance
in fresh tumour samples resected from patients, we treated isolated
tumour cells with cisplatin or gemcitabine in the presence or
absence of DEX ex vivo. We found that DEX promoted
proliferation in all of 10 examined lung carcinomas despite the
presence of cisplatin. These ex vivo data together with the recently
published in vitro and in vivo xenograft data (Herr et al, 2003)
suggest a need for carefully considering the use of DEX and other
GCs together with cytotoxic therapy in the curative treatment of
patients with lung carcinoma.
MATERIALS AND METHODS
Isolation of fresh tumour cells from resected lung cancer
specimens
Solid tumours from fresh lung carcinomas were minced in RPMI
medium supplemented with 20% heat-inactivated foetal bovine
serum (Sigma, Deisenhofen, Germany), 25mM HEPES, 2mM
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Paisley, Scotland) under sterile conditions, counted by trypan blue
exclusion and immediately analysed by the MTT-assay. Patient
material was obtained under the approval of the ethic committee of
the University of Heidelberg. Diagnoses were established by
conventional clinical and histological criteria according to the
World Health Organisation (WHO). All surgical resections were
indicated by principles and practice of oncological therapy.
Neither GCs nor neoadjuvant chemotherapy were applicated prior
to surgery. Tumour types and stages are shown in the Table 1.
Cell culture
The established P693 lung carcinoma cell line (NSCLC) is
described and was grown at 371C in DMEM (Life Technologies
Gibco BRL, Karlsruhe, Germany), supplemented with 10% foetal
bovine serum (Life Technologies).
Drugs
A stock solution of cisplatin (Sigma) was prepared in DMSO at
the concentration of 33mM. Gemcitabine (kind gift from Eli Lilly,
Indianapolis, IN, USA) was diluted in PBS to a 50mM stock. A
25mM stock of DEX (Sigma) was prepared in ethanol. Final
concentrations of the solvents in medium were 0.01% or less. We
used DEX in concentrations between 0.1 and 10mM since these
amounts are comparable with the clinical setting where one dose
of 12mg DEX (about 0.15mgkg
 1) resulted in plasma concen-
trations of 0.25–0.5mM with a half-life of several hours (Brady
et al, 1987). We employed cisplatin in concentrations of 7–34mM,
which are within the range found in tumours and plasma of
patients treated with a single dose of 150mgm
 2 cisplatin
(Tegeder et al, 2003).
MTT assay
Freshly isolated tumour cells were resuspended at a final
concentration of 5 10
5ml
 1 and plated in 96-well microplates,
100ml per well. Dexamethasone was added immediately and the
microplates were maintained in a 5% CO2 incubator. Cisplatin or
gemcitabine were added 24h later. At 48h after incubation of
cisplatin 10ml of a 10mgml
 1 MTT-solution (3-[4,5-dimethyl
thiazo-2-yl]-2,5-diphenyltetrazolium bromide, from Sigma) were
added. At 8h later medium was replaced by dimethyl sulphoxide
(Serva, Heidelberg, Germany) followed by incubation at 371C for
5min. The optical density of wells (intensity of blue colour
depending on mitochondrial activity) was measured by an ELISA
reader at 550nm wavelength.
RESULTS AND DISCUSSION
Since recent findings describing DEX-induced therapy resistance
in human carcinomas including lung cancer (Herr et al, 2003;
Rutz, 2002; Rutz and Herr, 2004) may be relevant for the treatment
of patients, we studied the effect of DEX on tumour cells freshly
isolated from resected lung tumour specimens. Cisplatin strongly
reduced cell viability in all carcinoma samples derived from
patients 1 to 10, whereas the presence of DEX prevented this effect
(Figure 1a–d). These data include five adenocarcinomas
(Figure 1a), four squamous cell carcinomas (Figure 1b, c) and
one small cell carcinoma (Figure 1d, compare also Table 1).
Furthermore, DEX prevented also the cytotoxic effect of gemcita-
bine (Figure 1c). To examine whether this effect might be due to
enhanced proliferation or inhibited cell death, we counted viable
and dead tumour cells 2, 4 and 6 days after treatment with cisplatin
in the presence or absence of DEX. Whereas cisplatin reduced the
amount of viable cells and enhanced the amount of dead cells, the
presence of DEX inhibited this effect as shown for patient no. 9 and
3 (Figure 2a). Since primary lung tumour cells are not suited for
long-term studies, we examined long-term survival using the
NSCLC cell line P693. Cells were treated with cisplatin in the
presence or absence of DEX. After 2 and 3 weeks, cells were
photographed and counted by trypan blue exclusion. After 2 weeks
more than 90% and after 3 weeks 100% of the cells treated with
cisplatin alone were dead. Cells treated with cisplatin in the
presence of DEX were swollen and showed typical features of
necrotic cell death. However, these cells recovered and started to
grow again 3 weeks after cisplatin (Figure 2b).
GCs are known to exert proapoptotic and antiproliferative
effects in lymphoid cells, and to reduce many of the symptoms
caused by tumours as well as their treatment. Hence, these agents
are widely used in cancer therapy including the highly effective
synthetic GC DEX (Rutz, 2002; Rutz and Herr, 2004). Our present
data demonstrate induction of resistance toward cytotoxic therapy
in lung cancer samples by ex vivo cotreatment with GCs. We report
here that DEX blocked the therapeutic effect in tumour cells
isolated from resected lung cancer specimens. These results are not
specific for cisplatin since DEX inhibited also gemcitabine-induced
apoptosis in our studies, which confirm recent data found in a lung
cancer cell line (Bergman et al, 2001). Also, DEX has been shown
to induce resistance toward diverse other cytotoxic agents used in
cancer therapy and also in many different malignant cell types in
vitro (Rutz, 2002; Rutz and Herr, 2004).
Furthermore, DEX enhanced basal viability in most of the 10
examined lung tumour samples, whereas basal viability was
inhibited in one sample and no effect was seen in another one.
We actually do not know the reason for these variations ex vivo,
but assume that they might be due to intrinsic properties of the
tumours and the quality of preparations of lung carcinoma cells.
Therefore, clearly more ex vivo experiments and clinical studies
are really needed. However, the results are so potentially very
important for the outcome of therapy that we feel they have to be
reported now.
The mechanisms by which GCs induce apoptosis in lymphoid
cells are well studied. These include depolarisation of the
mitochondrial membrane potential, enhanced expression of the
death receptor CD95 and its ligand, followed by activation of the
caspase cascade (Kofler, 2000; Planey and Litwack, 2000;
Distelhorst, 2002). The same mechanisms that are induced in
lymphoid cells have been shown to be blocked in several
carcinoma cells by GCs, thereby inhibiting chemo- and radiatio-
induced apoptosis (Herr et al, 2003; Wu et al, 2004). An open
question is, how do GCs mediate these cell-type specific effects that
have been clearly shown to be related to a functional glucocorti-
coid receptor (GR) (Herr et al, 2003; Wu et al, 2004). An
explanation for the cell-type specific antiapoptotic properties of
GCs may be the differential expression of GR coactivators and
Table 1 Characterisation of lung tumour tissue from patients 1–10
Patient
no. Gender
Age
(years)
Histological typing
(WHO) pTNM
1 M 70 Adenocarcinoma pT2N2M0 G3
2 M 60 Adenocarcinoma pT2N0M0 G2
3 M 54 Adenocarcinoma pT3N0M0 G3
4 F 64 Adenocarcinoma pT2N2M0 G3
5 M 47 Adenocarcinoma pT4N2M0 G3
6 M 60 Squamous cell carcinoma pT3N3M0 G3
7 M 75 Squamous cell carcinoma pT4N0M0 G2
8 F 45 Squamous cell carcinoma pT2N0M0 G3
9 M 55 Squamous cell carcinoma pT2N0M0 G3
10 F 66 Small cell carcinoma pT2N2M0 G3
M¼male; F¼female.
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Figure 1 DEX promotes cisplatin- and gemcitabine-inhibited viability of fresh lung carcinoma sample. Tumour cells from (A) five adenocarcinomas (B, C)
four squamous cell carcinomas and (D) one small cell carcinoma were isolated and were cultivated in a concentration of 5 10
5ml
 1 in the absence (white
bars) or presence of DEX (0.1, 1 or 10mM as indicated) for 24h. Thereafter, cisplatin or gemcitabine were added in concentrations indicated or not (CO)
and viability was measured by the MTT-assay after additional 48h. Eight wells per treatment were analysed and s.d. were less than 10%.
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opposite effects of tamoxifen on mammary vs endometrial tissue
(Shang and Brown, 2002). A recent study compared gene
expression of a breast cancer cell line with genes found to be
regulated by DEX in lymphocytes (Wu et al, 2004). Surprisingly,
only a few of the genes regulated by DEX in carcinomas are the
same as those identified as GC-regulated in lymphocytes. Among
the differentially regulated set of sequences are apoptotic genes as
well as genes involved in signal transduction, metabolism,
transcription, cell cycle, DNA repair and others (Rutz, 2002; Rutz
and Herr, 2004). These data strongly suggest that tissue-specific
differences in GC-induced apoptosis vs survival outcomes may be
due to cell-type-specific transcriptional regulation.
In conclusion, we have shown that application of DEX renders
lung cancer cells from fresh tumour tissue and not only
established carcinoma cell lines that have undergone a selection
process resistant to cytotoxic therapy with cisplatin and
gemcitabine. This finding urges carefully reconsideration of the
widespread use of GCs in treatment protocols for patients with
lung cancer. Alternatively, nonsteroidal agents such as serotonin-
receptor antagonists or the new NK1 receptor antagonists may
be sufficient to effectively manage at least some of the tumour
and treatment related symptoms, particularly, nausea and
emesis.
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Figure 2 DEX promotes proliferation and inhibits drug-induced death of fresh lung carcinoma samples. (A) Freshly isolated tumour cells from patient 3
and 9 were cultivated in a concentration of 5 10
5ml
 1 in the absence or presence of DEX (1mM) for 48h as indicated. Cisplatin (CIS, 17mM) was added or
not as indicated and viable or dead cells were counted by trypan blue exclusion 2, 4 or 6 days (d) later. s.d. are shown and were less than 10%. (B) P693 lung
carcinoma cells were treated as described above and cells were photographed 2 and 3 weeks later.
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